Gosatuzumab (Todavi) current market price and purchasing reference information

Gosatuzumab (trade name: Trodelvy, English name: Trodelvy) is an antibody-drug conjugate (ADC), mainly used to treat advanced triple-negative breast cancer (TNBC) and certain types of urothelial cancer. This drug was developed by Gilead. It has a significant effect of targeting and killing tumor cells and is an important progress in the current field of advanced breast cancer treatment. In 2024, gosatuzumab will be officially launched in China, providing a new treatment option for domestic patients with related cancers.

Although Tudavi has been approved for marketing in China, it has not been included in the national medical insurance directory so far, which means that patients need to pay the full amount out of pocket when using the drug. It is understood that the price of this drug in domestic hospitals is about 8000 for a box of multi-variables, and the specifications are mostly 180mg/7.5ml/ bottles (concentrated injection). The specific price may vary depending on the hospital, region, and channel. Patients are advised to consult the local hospital pharmacy or pharmaceutical administration department for the latest price information before purchasing the drug.

For some patients, the cost burden of Tudavi may be heavy, especially when multiple cycles of continuous treatment are required, and the total treatment cost may reach tens of thousands of yuan. However, there are also some regions or charity projects that provide certain assistance channels. Patients can find out through doctors or patient organizations whether there are free drugs, assistance plans or medical assistance to relieve financial pressure. In addition, there is currently no legal generic version of gosatuzumab on the market, so patients can only purchase the original drug through formal channels.

Overall, gosatuzumab, as an innovative targeted drug, has shown good efficacy in the treatment of refractory tumors such as triple-negative breast cancer. Its launch in China has brought new hope for survival to many patients. Although it has not yet been included in medical insurance, as the user population expands and policy evaluation progresses, its medical insurance coverage is expected to expand in the future. Patients should use it rationally under the guidance of professional doctors, and pay attention to policy changes and assistance project developments.

Reference materials:https://www.trodelvy.com/